和其它跨国制药公司上百年的悠久历史相比,诺和诺德公司将近80年的历史只能算是一个处在茁壮成长时期的年轻人,但就在这不算长的时期里,诺和诺德已发展为世界上最大的生物制药公司之一,成为世界糖尿病领域的主导。尤其是去年年底该公司的大动作——在中国北京建立从事基础研究的研发中心,引起医药界和媒体的广泛关注。 Compared with the long history of hundreds of other multinational pharmaceutical companies, Novo Nordisk nearly 80 years of history can only be regarded as a young man in a period of strong growth, but in this not a long period of time, Germany has developed into one of the largest biopharmaceutical companies in the world and has become the world leader in diabetes. In particular, the company’s big move at the end of last year, the establishment of an R & D center engaged in basic research in Beijing, China, has aroused widespread concern in the pharmaceutical industry and the media.